@FiercePharma: Australia looks to save cash by cutting scripts for common drugs. FiercePharmaAsia report | Follow @FiercePharma
@EricPFierce: Novo makes sure Denmark gets some of the action as it starts massive build up. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: Allergan pumps up its sales rep tally amid Viberzi launch, aesthetics push. FiercePharmaMarketing story | Follow @CarlyHFierce
> Roche ($RHHBY) is "absolutely convinced" that its new meds will offset biosimilar threats to its older drugs. More
> EU regulators have found no safety concerns linking GlaxoSmithKline's ($GSK) and Merck's ($MRK) HPV shots with two conditions known as complex regional pain syndrome and postural orthostatic tachycardia syndrome. More
> Endo ($ENDP) CEO Rajiv De Silva is working to distance himself and his company from his embattled former employer, Valeant ($VRX). More
Medical Device News
@FierceMedDev: Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss. More | Follow @FierceMedDev
@VarunSaxena2: IYCMI from FierceDrugDelivery: Investigational drug enables faster absorption of bioresorbable drug-eluting stents. Article | Follow @VarunSaxena2
@EmilyWFierce: Medicaid calls on Gilead, AbbVie to answer hep C drug pricing questions. FiercePharma article | Follow @EmilyWFierce
> GAO study finds 510(k)-cleared devices account for 94% of unplanned postmarket safety studies. More
> Theranos scouts out new lab director amid testing fallout. Article
Biotech News
@FierceBiotech: Gilead wins FDA approval for a new HIV combo pill with rivals at its heels. Report | Follow @FierceBiotech
@JohnCFierce: Andy Futreal at MD Anderson is joining my Big Data:2025 panel at #JPM16. | Follow @JohnCFierce
> AstraZeneca poaches ZS Pharma for $2.7B, beating Actelion to the punch. Report
> Sanofi bets another $1.7B on diabetes to pad its lagging pipeline. Story
> Under Pfizer's gaze, Allergan's Saunders softens his tone on early-stage R&D. Article
And Finally... Injuries from Mylan's ($MYL) Epipen are rare but have the potential to be serious for children. Report